NR4A1 and breast cancer: Irrespective of the chemotherapy agent administered, iatrogenic amenorrhea is associated with an increased survival rate in oestrogen receptive (ER)-positive breast cancer [2, 3], and amenorrhea is a surrogate marker for effective treatment in hormone receptor-positive pre-menopausal breast cancer patients [4].